Treatment of patients with chronic hepatitis B who have failed previous antiviral treatment with pegylated interferon α2a (40 kda; PEGASYS )
|
|
- Janis Lester
- 5 years ago
- Views:
Transcription
1 Original article Antiviral Therapy 13: Treatment of patients with chronic hepatitis B who have failed previous antiviral treatment with pegylated interferon α2a (40 kda; PEGASYS ) Henry L-Y Chan*, Vincent W-S Wong, Angel M-L Chim, Grace L-H Wong, Hoi-Yun Chan and Joseph J-Y Sung Department of Medicine and Therapeutics and Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong SAR, China *Corresponding author: hlychan@cuhk.edu.hk Background: Although nucleot(s)ide analogues can effectively suppress hepatitis B virus (HBV) replication, many patients experience relapse of hepatitis after cessation of treatment. We aimed to investigate the efficacy of pegylated interferon α2a (PEG-IFN-α2a) in these difficult-to-treat patients. Methods: Chronic hepatitis B patients who have received antiviral drugs for 12 months and stopped for 6 months were treated by 48-week PEG-IFN-α2a. Virological response was defined as HBV DNA <10,000 copies/ml and hepatitis B e antigen (HBeAg) seroconversion (for HBeAg-positive patients). Results: A total of 40 patients, 29 HBeAg-positive and 11 HBeAg-negative, with median log 10 HBV DNA 7.3 copies/ml and alanine aminotransferase 110 IU/ml were studied. The last antiviral treatment was given for 92 ±61 weeks and stopped for 176 ±88 weeks. At the end of treatment, 22 (12 HBeAg-positive and 10 HBeAg-negative; 55%) patients had virological response and 16 (7 HBeAg-positive and 9 HBeAg-negative; 40%) patients had undetectable HBV DNA (<100 copies/ml). At 24 weeks post-treatment, 14 (8 HBeAg-positive and 6 HBeAgnegative; 35%) patients had virological response and 9 (5 HBeAg-positive and 4 HBeAg-negative; 23%) patients had undetectable HBV DNA. Two (5%) patients had lost hepatitis B surface antigen. HBV DNA levels at week 24 best predicted sustained virological response (area under curve 0.76, 95% confidence interval , P=0.007). At HBV DNA cutoffs of 3 logs and 5 logs at week 24, the sensitivity/specificity for sustained virological response were 50%/85% and 86%/62%, respectively. Conclusions: PEG-IFN-α2a was effective in the treatment of chronic hepatitis B patients who have failed previous antiviral treatment. Introduction Chronic hepatitis B virus (HBV) infection is the most common cause of liver cirrhosis and hepatocellular carcinoma in Asia. Persistent high viraemia and hepatic necroinflammation is associated with a higher risk of liver-related complications including hepatocellular carcinoma [1,2]. Nucleos(t)ide analogues such as lamivudine have potent antiviral activities that can effectively suppress the replication of HBV. In hepatitis B e antigen (HBeAg)-positive patients, HBeAg seroconversion is usually regarded as an indicator of successful viral clearance. However, up to 50% of patients had HBV reactivation and hepatitis relapse after stopping lamivudine treatment despite HBeAg seroconversion [3,4]. There is increasing evidence that extended antiviral treatment after HBeAg seroconversion can consolidate the viral suppression and reduce the risk of post-treatment relapse [5]. Therefore, most of the current treatment guidelines recommend treatment cessation after patients have developed HBeAg seroconversion for over 6 months [6 8]. In a placebo-controlled, randomized trial of 2-year lamivudine treatment among HBeAg-negative patients, approximately two-thirds of patients had HBV DNA >10,000 copies/ml and 40% of patients had elevated alanine aminotransferase (ALT) within 6 months after stopping lamivudine [9]. The failure of viral clearance by antiviral agents might be related to their weak efficacy to clear the covalently closed circular (ccc) DNA inside the hepatocytes [10,11]. Pegylated interferon α2a (PEG-IFN-α2a), either used alone or in combination with lamivudine, has been shown to induce virological response in approximately one-third of HBeAg-positive patients and 43% of HBeAg-negative patients at 6 months post-treatment [12 16]. The virological response tends to be sustained 2008 International Medical Press
2 HL-Y Chan et al. in the majority of patients for at least up to 3 years [17,18]. The efficacy of PEG-IFN-α2a to clear cccdna seems to be superior to that of nucleos(t)ide analogues [19,20]. In a subgroup analysis of a previous clinical trial, patients who have previous exposure to antiviral agents responded equally well to PEG-IFN-α2a as the treatment-naive patients [21]. However, the previous antiviral treatments in these patients were not clearly documented and it was uncertain whether the treatment was adequate. In this study, we aimed to investigate the efficacy of PEG-IFN-α2a among a cohort of chronic hepatitis B patients who have failed previous antiviral treatment. These patients must have received a minimum of 1 year treatment but still have active viraemia and disease activity for at least 6 months after stopping treatment. In other words, these patients were unlikely to develop spontaneous disease remission and were difficult-totreat. Predictors of virological response to PEG-IFN-α2a were also investigated in this study. Methods Patients Chronic hepatitis B patients were recruited from the Hepatitis Clinic of the Prince of Wales Hospital (Shatin, Hong Kong) between April 2005 and October Eligible patients must be aged years and have positive hepatitis B surface antigen (HBsAg) for at least 6 months. The serum HBV DNA must be at least 100,000 copies/ml and ALT must be 1.5- to 10- fold higher than the upper limit of normal at the screening visit. Both HBeAg-positive and HBeAgnegative patients were recruited. As this study was designed to evaluate patients who did not respond to an adequate trial of antiviral treatment, patients must have a documented history of previous treatment by nucleos(t)ide analogues for at least 1 year and the treatment must have been stopped for at least 6 months before the screening visit. The reason for previous treatment cessation could be treatment failure, part of the clinical trial or mutual agreement between the physician and the patient. Patients were excluded if they had coinfection with hepatitis C virus (HCV) or human immunodeficiency virus (HIV), decompensated liver disease, history of hepatocellular carcinoma, other causes of liver disease, serious medical or psychiatric illness, or concurrent use of corticosteroid or immunosuppressive agents. Women of child-bearing age must have negative urine pregnancy test before recruitment. The study was conducted in accordance with the guidelines of the Declaration of Helsinki. The protocol was approved by the local ethics committee. All patients gave witnessed written informed consent before enrolment. Study design This study was a single-centred, open-labelled study of PEG-IFN-α2a (Pegasys ; F Hoffmann-La Roche, Basal, Switzerland) for the treatment of chronic HBV infection that failed previous antiviral treatment. PEG-IFN-α2a was prescribed as subcutaneous injections at a dose of 180 μg/week for 48 weeks. Treatment was commenced within 4 weeks of the screening visit. HBV genotype and genotypic resistance to lamivudine and adefovir were checked at the baseline visit. Patients were monitored at weeks 1, 2, 4, 8, 12, 16, 24, 32, 40 and 48 for liver biochemistry, virology tests, adverse events and drug compliance. Patients were followed-up at weeks 52, 56, 60 and 72 after cessation of treatment. The investigators interviewed the patients for symptomatic adverse effects and monitored laboratory tests closely at each follow-up visit. The severity of adverse events were assessed according to a preset table and classified into mild (grade 1), moderate (grade 2), severe (grade 3) and life-threatening (grade 4). The dosage of PEG-IFN-α2a was reduced from 180 μg/week to 135 μg/week for grade 3 adverse events (or sometimes grade 2 adverse events at the discretion of the investigator). The dosage could be further reduced to 90 μg/week and then to 45 μg/week if the adverse events persisted or recurred despite initial dose reduction. PEG-IFN-α2a was stopped in cases of grade 4 adverse events. Laboratory assays Serological assays HBsAg was tested using commercially available ELISA kits (COBAS CORE HBsAg IIEIA, Roche Diagnostics Corporation, Indianapolis, IN, USA) and confirmed by a neutralization assay. Antibodies against HCV (anti- HCV, third generation assay) and HIV (anti-hiv) were tested using commercially available ELISA kits (Abbott GmBH Diagnostika, Wiesbaden-Delkenheim, Germany). HBeAg and antibodies to HBe (anti-hbe) were measured by ELISA assays (Sanofi Diagnostics, Pasteur, France). Virological assays Residual serum samples were stored at -80 C. HBV DNA was extracted by QIAGEN QIAamp DNA Mini Kit (QIAGEN Inc., Chatsworth, CA, USA) according to the instructions of the manufacturer. HBV DNA was quantified by TaqMan real-time PCR assay as described previously [22,23]. The range of HBV DNA detection was copies/ml with correlation coefficient of the standard curve routinely > HBV genotyping was determined by restriction fragment length polymorphism and confirmed by direct sequencing in case of doubt in the residual serum samples at the initial visit, as described previously International Medical Press
3 Pegylated interferon for antiviral failure [24,25]. Lamivudine- and adefovir-resistant mutants were determined by the INNO-LiPA HBV DR2 assay according to the instructions of the manufacturer (Innogenetics N.V., Ghent, Belgium) [26]. Endpoints The primary endpoint of this study was virological response, which was defined as HBV DNA <10,000 copies/ml (plus HBeAg seroconversion in HBeAg-positive patients) at 24 weeks post-treatment (week 72). Secondary endpoints included HBeAg seroconversion, HBV DNA undetectable by PCR, ALT normalization at the end of treatment (week 48) and 24 weeks post-treatment (week 72). The ability of baseline characteristics and residual HBV DNA at various stages of PEG-IFN-α2a treatment to predict 24-week post-treatment virological response was also evaluated. We defined ALT flare during PEG-IFN-α2a treatment as pretreatment baseline level plus ALT increase of >116 IU/l (that is, 2 upper limit of normal) at any time during treatment [17,27]. Statistical analysis On the basis of previous studies of PEG-IFN-α2a among treatment-naive patients, 24-week post-treatment virological response was 32% among HBeAg-positive patients and 43% among HBeAgnegative patients [14,15]. To determine a virological response of up to 35% with half-width 95% confidence interval (CI) of 15%, 39 patients needed to be recruited for this study (INSTAT, GraphPad Software Inc, San Diego, CA, USA). Treatment response was analyzed by intention-to-treat analysis. All patients who were recruited for PEG-IFNα2a treatment were included in the analysis and any patient withdrawal or missing data was regarded as treatment failure. For the analysis of adverse events, all patients who received at least one dose of PEG-IFN-α2a were included. Statistical tests were performed by SPSS (version 11.0, Chicago, IL, USA). Continuous variables were expressed as median (range) due to our small sample size. HBV DNA was logarithmic transformed for analysis. Percentages of patients that achieved key outcome measures were presented as 95% CI by the central limit theorem on binomial distribution. Continuous variables were compared using Mann Whitney U test. Categorical variables were compared using Pearson χ 2 test or Fisher s exact test as appropriate. Logistic regression analysis was used to determine the baseline predictors of virological response at 24 weeks post-treatment. Continuous variables (age, ALT, log 10 HBV DNA) were categorized into binary variables by their respective median values in the logistic regression analysis. Area under the curve (AUC) was used to determine the predictive values of baseline and residual HBV DNA at different time intervals for sustained virological response. Statistical significance was taken as P-value <0.05. All statistical tests were two-sided. Results Clinical characteristics A total of 29 HBeAg-positive and 11 HBeAg-negative chronic hepatitis B patients were recruited in this study (Table 1). Before this study, 36 patients had received one antiviral agent (three patients had emtricitabine and 33 patients had lamivudine) and four patients had received two antiviral agents (three patients had emtricitabine and lamivudine, one patient had lamivudine and adefovir dipivoxil). Two patients had received an additional 6 month conventional interferon-α before the antiviral therapy. The duration of the last antiviral treatment was 92 ±61 (range ) weeks and the duration of off-treatment follow-up before recruitment was 176 ±88 (range ) weeks. During the last antiviral treatment, 20 of the 29 HBeAg-positive patients had undergone HBeAg seroconversion for a median of 41 (range 0 401) weeks and nine patients were persistently HBeAg-positive. Among the 20 patients who had HBeAg seroconversion (and subsequent reversion to positive HBeAg before this study), eight patients had HBV DNA available and four (50%) of them had HBV DNA suppressed to <10,000 copies/ml at the time of treatment cessation. Among 29 HBeAgpositive patients, 22 stopped the last antiviral treatment according to the protocol in clinical trials and the remaining seven patients stopped treatment based on the mutual decision of the physician and the patient. Among the 11 HBeAg-negative patients, five patients were initially HBeAg-positive and developed HBeAg seroconversion (only one patient had end-of-treatment HBV DNA available at 27,200 copies/ml) while six patients were persistently HBeAg-negative (three of six patients who had HBV DNA available at the end of treatment had HBV DNA suppressed to <10,000 copies/ml) during the last antiviral treatment. Among the 11 HBeAg-negative patients, eight had antiviral treatment stopped according to the protocol of the clinical trial. Overall, 14 (10 HBeAg-positive and four HBeAg-negative) patients were tested for the presence of lamivudine-resistant mutations at the end of the last antiviral treatment and three patients had the rtm204i mutation. At baseline, 18 (45%) patients had ALT >2 upper limit of normal. Liver cirrhosis was detected on ultrasound in 13 (33%) patients, but none of the patients underwent a liver biopsy within the 6 months of treatment. Two patients had pre-existing lamivudineresistant mutations (one patient with rtm204m/i and Antiviral Therapy 13:4 557
4 HL-Y Chan et al. Table 1. Clinical patient characteristics HBeAg-positive HBeAg-negative Overall Characteristic n=29 n =11 n =40 Male, n (%) 23 (79) 9 (82) 32 (80) Median age, years (range) 45 (25 60) 49 (38 61) 45 (25 61) Median body mass index, kg/m 2 (range) 23.8 ( ) 25.1 ( ) 24.6 ( ) Median platelet count, 10 9 cells/l (range) ( ) ( ) ( ) Median international normalized ratio (range) 1.05 ( ) 1.07 ( ) 1.06 ( ) Median albumin, g/l (range) 44.0 ( ) 44.0 ( ) 44.0 ( ) Median bilirubin, μmol/l (range) 14.0 ( ) 15.0 ( ) 14.0 ( ) Median alanine aminotransferase, IU/l (range) ( ) ( ) ( ) Median log 10 HBV DNA, copies/ml (range) 7.5 ( ) 6.8 ( ) 7.3 ( ) HBV genotype B, n C, n D, n 1 1 Lamivudine resistance, n (%) 2 (7) 0 (0) 2 (5) Early withdrawal, n (%) 2 (7) 0 (0) 2 (5) HBeAg, hepatitis B virus e antigen; HBV, hepatitis B virus. Table 2. Treatment response at end of treatment and 24 weeks post-treatment (sustained response) End of treatment (week 48) 24 weeks post-treatment (week 72) HBeAg- HBeAg- HBeAg- HBeAg- Patients All n=40 positive n=29 negative n=11 P-value All n=40 positive n=29 negative n=11 P-value Virological 22 (55%) 12 (41%) 10 (91%) (35%) 8 (28%) 6 (55%) 0.11 response* HBeAg NA 14 (48%) NA NA NA 15 (52%) NA NA seroconversion HBV DNA 25 (63%) 15 (52%) 10 (91%) (35%) 8 (28%) 6 (55%) 0.11 <10,000 copies/ml Undetectable 16 (40%) 7 (24%) 9 (82%) (23%) 5 (17%) 4 (36%) 0.20 HBV DNA ALT normal 20 (50%) 12 (41%) 8 (73%) (63%) 14 (48%) 11 (100%) *Virological response defined as HBV DNA <10,000 copies/ml (plus hepatitis B e antigen [HBeAg] seroconversion in HBeAg-positive patients). ALT, alanine aminotransferase; HBV, hepatitis B virus; NA, not applicable. another with rtm204m/i/v). One patient withdrew due to mild alopecia and gum bleeding at week 21 and another patient withdrew at week 24 due to hypothyroidism. A total of 38 patients completed per protocol treatment and follow-up. End-of-treatment response At the end of treatment, 22 (55%; 95% CI 25 57%) patients achieved virological response (HBV DNA <10,000 copies/ml and HBeAg seroconversion for HBeAg-positive patients), including 12 (41%; 95% CI 24 61%) HBeAg-positive patients and 10 (91%; 95% CI %) HBeAg-negative patients (P=0.002; Table 2). No patients had HBeAg loss alone without the development of anti-hbe antibodies. HBeAg-negative patients responded better than HBeAg-positive patients in terms of the percentage of patients with HBV DNA <10,000 copies/ml (P=0.022) and undetectable HBV DNA (P=0.001). The percentages of patients who achieved normal ALT levels were comparable between HBeAg-positive and HBeAg-negative patients (P=0.077). Post-treatment response At 24 weeks post-treatment, virological response was achieved in 14 (35%; 95% CI 21 52%) patients, including eight (28%; 95% CI 13 48%) HBeAg-positive patients and six (55%; 95% CI 25 82%) HBeAg-negative patients (P=0.11; Table 2). Among the eight HBeAg-positive responders, seven patients also had end-of-treatment virological response while the remaining patient had positive HBeAg and undetectable HBV DNA at the end of treatment. The International Medical Press
5 Pegylated interferon for antiviral failure Table 3. Baseline predictors of virological response at 24 weeks post-treatment Variable Responder, n (%) Non-responder, n (%) Odds ratio 95% confidence interval P-value Age >45 years 8 (57%) 11 (42%) Gender, male 12 (86%) 20 (77%) Alanine aminotransferase 5 (36%) 14 (54%) >110 IU/l Log 10 HBV DNA (copies/ml) 4 (29%) 16 (62%) >7.3 copies/ml HBV genotype C 9 (64%) 19 (73%) Lamividine-resistant mutation 1 (7%) 1 (4%) Continuous variables (age, alanine aminotransferase, log 10 HBV DNA) were categorized into binary variables by their respective median values in the logistic regression analysis. HBV, hepatitis B virus. Table 4. Prediction of virological response at 24 weeks post-treatment by HBV DNA at different time intervals Log 10 HBV DNA, copies/ml Week Responder (n=14)* Non-responder (n=26)* AUC 95% confidence interval P-value ± ± ± ± ± ± ± ± ± ± ± ± *Values expressed as median (±SD). AUC, area under the curve; CI, HBV, hepatitis B virus. percentages of HBeAg-positive and HBeAg-negative patients who had HBV DNA <10,000 copies/ml (P=0.11) and undetectable HBV DNA (P=0.20) became comparable 6 months after stopping PEG-IFNα2a. Among the two patients who had pre-existing lamivudine resistant-mutants (both had positive HBeAg at baseline), one (50%) of them achieved sustained virological response. Among the 14 patients who had virological response at week 24 post-treatment, 11 of them reached 1 year post-treatment follow-up at the time of analysis. Out of these 11 patients, eight (73%) remained in virological response at 1 year post-treatment. The remaining three patients (two patients had positive HBeAg and one patient had negative HBeAg at baseline) remained HBeAg-negative but had reactivation of HBV DNA from 622,900 to 2,180,000 copies/ml. Two (5%) patients developed HBsAg loss at the end of treatment and sustained this loss until 24 weeks after treatment. One of them had genotype C HBV infection with positive HBeAg, HBV DNA 8.3 log 10 copies/ml and ALT 196 IU/l at baseline. Another patient had genotype B HBV infection with negative HBeAg, HBV DNA 6.2 log 10 copies/ml and ALT 140 IU/l at baseline. Predictors of 24-week post-treatment virological response Responders to PEG-IFN-α2a treatment tended to have lower HBV DNA at baseline but the difference fell short of statistical significance (Table 3). Otherwise, no baseline variable including age, gender, ALT level, HBeAg status, HBV genotype or pre-existing lamivudine-resistant mutation could predict virological response at 24 weeks post-treatment. Serial HBV DNA measurements suggested that residual HBV DNA at week 24 could best predict post-treatment virological response (Tables 4 and 5). At week 24, a HBV DNA cut-off of 1,000 copies/ml had sensitivity, specificity, positive and negative predictive values for post-treatment virological response of 50%, 85%, 64% and 76%, respectively. At a HBV DNA cut-off of 100,000 copies/ml at week 24, the sensitivity, specificity, positive and negative predictive values for post-treatment virological response were 86%, 62%, 55% and 89%, respectively. ALT flare during PEG-IFN-α2a treatment had a marginal association with virological response at 24 weeks post-treatment. Eight of 14 (57%) patients who had ALT flare versus six of 26 (23%) patients without ALT flare developed virological response at 24 weeks post-treatment (P=0.043). There was no difference in the frequency of ALT flares among HBeAg-positive (11 Antiviral Therapy 13:4 559
6 HL-Y Chan et al. of 29; 38%) and HBeAg-negative (3 of 8; 38%) patients (P=0.72). Safety Most of the adverse events were mild to moderate (Table 6). Five patients developed serious adverse events: two patients developed feverish reaction requiring hospitalization after the first dose of PEG- IFN-α2a; one patient developed upper gastrointestinal bleeding due to Mallory Weiss syndrome at week 16; one patient was admitted for upper respiratory tract infection at week 56 (post-treatment week 8) and one patient developed hypothyroidism at week 24. The patients who developed hypothyroidism withdrew from study and the thyroid function test results returned to normal on thyroxine replacement therapy. Dosage adjustment was needed for thrombocytopenia (one patient), neutropenia (one patient) and hyperthyroidism (one patient, who was started on carbimazole treatment). Three additional patients needed dosage interruption of PEG-IFN-α2a due to elevated ALT levels at weeks of treatment. No patient died or required liver transplantation. Discussion In this study, we have demonstrated that the 24-week post-treatment virological response to PEG-IFN-α2a for patients who failed previous antiviral treatment was 35%. This response rate was comparable to that reported among treatment-naive patients in previous clinical trials [12 15]. Our patients had active liver disease for a mean of 176 months after cessation of their last course of antiviral treatment and two patients also failed a course of conventional interferon treatment. Although we did not have a control group, we believe that spontaneous disease remission could hardly account for the high virological response rate among our patients. In other words, PEG-IFN-α2a can be considered as a viable treatment option among patients who have failed previous antiviral treatment. At the end of treatment, nine of 11 (82%) HBeAgnegative patients had undetectable HBV DNA by PCR. This response was much higher than that achieved by 2-year lamivudine treatment in a placebocontrolled study (26%) and was comparable to that reported in the pivotal trial of PEG-IFN-α2a in HBeAg-negative patients (63%) [9,15]. We must admit a possible overestimation due to our small sample size, but the lower bound of the 95% CI was still 48%. The excellent virological suppression by PEG-IFN-α2a among HBeAg-negative patients in our study might be partly related to the relatively lower baseline HBV DNA than that of the HBeAg-positive patients. Nonetheless, we believe that augmentation of immune response is a very important mechanism for viral clearance in HBeAg-negative patients, among whom immune tolerance is less of a problem than in HBeAg-positive patients. Even among lamivudinetreated patients, a very high maintained response and low rate of drug resistance could be seen in severe acute exacerbation of chronic hepatitis B, which indicated a vigorous host immune clearance [28]. Unfortunately, in this study, approximately half of the patients could not sustain the virological response after stopping PEG-IFN-α2a treatment. Table 5. Performance of different HBV DNA levels at various time intervals of treatment for predicting virological response at 24 weeks post-treatment HBV DNA, Responder Non-responder Positive Negative Likelihood Week log 10 copies/ml (n=14) (n=26) Sensitivity, % Specificity, % predictive value, % predictive value, % ratio 4 < < < < < < < < < < < < < < HBV, hepatitis B virus International Medical Press
7 Pegylated interferon for antiviral failure Previous studies suggested that lower HBV DNA and higher ALT levels were associated with higher post-treatment virological response with PEG-IFN-α2a treatment [13,14]. However, this phenomenon could not be confirmed in our previous study with long-term post-treatment follow-up [17]. In this study, lower baseline HBV DNA had a tendency for higher 24-week post-treatment virological response but ALT levels did not predict the response. We believe that the response to pegylated interferon-based PEG-IFN-α2a therapy is largely related to the cccdna levels. Patients with lower baseline cccdna level tend to respond better to a combination of PEG-IFN-α2a and lamivudine treatment [19,29]. The use of quantitative serum hepatitis B surface antigen, which has a good correlation with the cccdna level, as a surrogate predictor of response should be evaluated in future clinical trials [10,20,29]. A roadmap model has been proposed by a group of hepatologists to guide the treatment strategy on the basis of on-treatment HBV DNA response [30]. Residual HBV DNA at 6 12 months has been found to predict viral suppression and drug resistance at 2 3 years [31 33]. In chronic hepatitis C, early viral response at week 12 can predict sustained virological clearance in genotype 1 hepatitis C virus infection [34]. In chronic hepatitis B, no on-treatment predictor for sustained response to PEG-IFN-α2a has been evaluated. In this study, we found that HBV DNA at week 24 could predict post-treatment virological response better than other earlier time intervals. However, the predictive ability was only modest with an AUC of only The sensitivity for post-treatment virological response was only 86% with HBV DNA >100,000 copies/ml at week 24. If PEG-IFN-α2a is stopped at week 24 for patients with unsatisfactory response, 14% of patients who had a chance to respond would have the treatment prematurely terminated. As we are uncertain whether treatment-naive patients respond differently to our patients who have failed previous antiviral treatment, we cannot extrapolate our results to all chronic hepatitis B patients using PEG-IFN-α2a at this stage. Our study is limited by the small sample size and lack of a control group. As the efficacy of PEG-IFNα2a in chronic hepatitis B has been well established by several large-scale, randomized, controlled trials, we did not aim to evaluate its efficacy versus placebo, which might not be ethical, or another active antiviral treatment in this study [16]. By contrast, this is a pilot, proof-of-concept study that PEG-IFN-α2a is effective among patients who have failed previous antiviral treatment. Therefore, we have a more stringent definition for antiviral failure than the subgroup analysis of previously conducted studies [21]. Unfortunately, some of these patients received per protocol antiviral Table 6. Adverse events (>5% occurrence) and laboratory abnormalities (grade 3 and 4) during the 72-week study period Adverse event n (%) Weight loss <5% 17 (42.5) >10% 7 (17.5) Upper respiratory tract infection 8 (20) Fever 24 (60) Alopecia 14 (35) Right upper abdominal discomfort 7 (17.5) Malaise 28 (70) Headache 17 (42.5) Myalgia 13 (32.5) Decreased appetite 14 (35) Erytherma at injection sites 24 (60) Skin allergy 4 (10) Vomiting or diarrhoea 6 (15) Laboratory abnormalities Elevated alanine aminotransferase 8 (20) Hypophosphataemia 2 (5) Thrombocytopenia 2 (5) Hypothyroidism 1 (2.5) treatment in previous clinical trials and did not fulfil the recommended criteria for treatment cessation of the recent practice guidelines [6 8]. The high rate of HBeAg reversion after the previous antiviral treatment might be related to the inadequate consolidation treatment after HBeAg seroconversion. Our sample size, albeit small, was adequate to show a reasonable sustained virological response to PEG-IFN-α2a even without a control group. In conclusion, PEG-IFN-α2a has satisfactory efficacy to treat chronic hepatitis B patients who have failed previous antiviral treatment. Before retreating these patients with long-term antiviral therapy, a finite course of PEG-IFN-α2a can be considered as an alternative if there is no contraindication. Acknowledgements We thank Roche (Hong Kong) for the supply of PEG- IFN-α2a for this study. We also thank Kelvin KF Tsoi for his invaluable advice on statistics. Disclosure statement Roche (Hong Kong) provided a free supply of PEG- IFN-α2a but no additional financial assistance. The authors had the final responsibility for the study protocol, case report forms, progress of the study, statistical analysis, reporting of data and manuscript submission. The authors had full access to the data files of the study. HL-Y Chan is an advisory board member of Schering Plough, Novartis Phamaceutical and Antiviral Therapy 13:4 561
8 HL-Y Chan et al. Bristol Myers Squibb. JJ-Y Sung received paid lecture fees from AstraZeneca Hong Kong Limited, GlaxoSmithKline Pharmaceuticals International and the American Society for Gastrointestinal Endoscopy. The other authors declare no conflicts of interest. References 1. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: Chan HL, Tse CH, Mo F, et al. High viral load and hepatitis B virus subgenotype Ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol 2008; 26: Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000; 32: van Nunen AB, Hansen BE, Suh DJ, et al. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut 2003; 52: Lee KM Cho SW, Kim SW, Kim HJ, Hahm KB, Kim JH. Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion. J Viral Hepat 2002; 9: Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: Liaw YF, Leung N, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 2005; 25: Keeffe EB, Dieterich DT, Han SH, et al. A treatment of algorithm for the management of chronic hepatitis B virus infection in the United States: An update. Clin Gastroenterol Hepatol 2006; 4: Chan HL, Wang H, Niu J, Chim AM, Sung JJ. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial. Antivir Ther 2007; 12: Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccdna during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126: Sung JJY, Wong ML, Bowden S, et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology 2005; 128: Chan HL, Leung NW, Hui AY, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-α2b and lamivudine with lamivudine alone. Ann Intern Med 2005; 142: Janssen HLA, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomized trial. Lancet 2005; 365: Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: Hui AY, Chan HL, Cheung A, Cooksley G, Sung JJ. Treatment of chronic hepatitis B virus infection by pegylated interferon: systematic review of 4 randomized studies. Aliment Pharmacol Ther 2005; 22: Chan HL, Hui AY, Wong VW, Chim AM, Wong ML, Sung JJ. Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B. Hepatology 2005; 41: Marcellin P, Bonino F, Lau GK, et al. Suppression of HBV DNA in patients with HBeAg-negative CHB treated with peginterferon alfa-2a (40KD) ± lamivudine: 2-year follow up results. 57th Annual Meeting of the American Association for the Study of Liver Diseases October 2006, Boston, MA, USA. Abstract Chan HL, Wong VW, Chim AM, et al. Virological response to different combination regimes of peginterferon alfa-2b and lamivudine in hepatitis B e antigen positive chronic hepatitis B. Antivir Ther 2007; 12: Wursthorn K, Lutgehetmann M, Dandri M, et al. Peginterferon alpha-2b plus adefovir induce strong cccdna decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006; 44: Flink HJ, Hansen BE, Heathcote EJ, et al. Successful treatment with peginterferon alfa-2b of HBeAg-positive HBV non-responders to standard interferon or lamivudine. Am J Gastroenterol 2006; 101: Chan HL, Chui AK, Lau WY, et al. Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation. J Med Virol 2002; 68: Loeb KR, Jerome KR, Goddard J, Huang ML, Cent A, Corey L. High-throughput quantitative analysis of hepatitis B virus DNA in serum using the TaqMan fluorogenic detection system. Hepatology 2000; 32: Lindh M, Andersson AS, Gusdal A. Genotypes, nt 1858 variants, and geographical origin of hepatitis B virus largescaled analysis using a new genotyping method. J Infect Dis 1997; 175: Chan HL, Tsang SW, Liew CT, et al. Viral genotype and hepatitis B virus DNA levels are correlated with histologic liver damage in HBeAg-negative chronic hepatitis B virus infection. Am J Gastroenterol 2002; 97: Hussain M, Fung S, Libbrecht E, et al. Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir. J Clin Microbiol 2006; 44: Nair S, Perrillo RP. Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B: Is sustained clearance of HBV DNA dependent on levels of pretreatment viraemia? Hepatology 2001; 34: Chan HL, Wong VW, Hui AY, et al. Long-term lamivudine treatment is associated with a good maintained response in severe acute exacerbation of chronic HBeAg-negative hepatitis B. Antivir Ther 2006; 11: Chan HL, Wong VW, Tse AM, et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol 2007; 5: Keeffe EB, Zeuzem S, Koff RS, et al. Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 2007; 5: Lai CL, Gane E, Liaw TF, et al. Maximal early HBV suppression is predictive of optimal virologic and clinical efficacy in nucleoside treated hepatitis B patients: scientific observations from a large multinational trial (The GLOBE Study). 56th Annual Meeting of American Association for the Study of Liver Diseases November 2005, Boston, MA, USA. Abstract Locarnini S, Qi X, Arterburn S, et al. Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB). 40th Annual Meeting of European Association for the Study of the Liver April 2005, Paris, France. Abstract Chan HL, Wong VW, Tse CH, et al. Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B. Aliment Pharmacol Ther 2007; 25: Davis GL. Monitoring of viral levels during therapy of hepatitis C. Hepatology 2002; 36 Suppl 1:S145 S151. Accepted for publication 24 February International Medical Press
Response-guided antiviral therapy in chronic hepatitis B: nucleot(s)ide analogues vs. pegylated interferon
Response-guided antiviral therapy in chronic hepatitis B: Sang Hoon Ahn, M.D., Ph.D. Department of Internal Medicine, Yonsei University College of Medicine, Institute of Gastroenterology, Liver Cirrhosis
More informationPrediction of HBsAg Loss by Quantitative HBsAg Kinetics during Long-Term 2015
THAI J 16 GASTROENTEROL Treatment with Nucleos(t)ide Original Analogues Article Prediction of HBsAg Loss by Quantitative HBsAg Kinetics during Long-Term Treatment with Nucleos(t)ide Analogues Sombutsook
More informationManagement of Chronic Hepatitis B in Asian Americans
Management of Chronic Hepatitis B in Asian Americans Myron J Tong; UCLA, CA Calvin Q. Pan; Mount Sinai, NY Hie-Won Hann; Thomas Jefferson, PA Kris V. Kowdley; Virginia Mason, WA Steven Huy B Han; UCLA,
More informationCornerstones of Hepatitis B: Past, Present and Future
Cornerstones of Hepatitis B: Past, Present and Future Professor Man-Fung Yuen Queen Mary Hospital The University of Hong Kong Hong Kong 1 Outline Past Natural history studies Development of HBV-related
More informationOur better understanding of the natural
TREATMENT OF CHRONIC HEPATITIS B: MASTERING THE BASICS ON A COMPLEX TOPIC Ke-Qin Hu, MD* ABSTRACT The availability of newer antiviral agents, as well as comprehensive treatment recommendations, has equipped
More informationManagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance
anagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance / 김강모 연수강좌 anagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance 김강모 울산대학교의과대학서울아산병원소화기내과
More informationPros and Cons of Peginterferon Versus Nucleos(t)ide Analogues for Treatment of Chronic Hepatitis B
Curr Hepatitis Rep (2010) 9:91 98 DOI 10.1007/s11901-010-0041-7 Pros and Cons of Peginterferon Versus Nucleos(t)ide Analogues for Treatment of Chronic Hepatitis B Milan J. Sonneveld & Harry L. A. Janssen
More informationHepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &
More information29th Viral Hepatitis Prevention Board Meeting
29th Viral Hepatitis Prevention Board Meeting Madrid, November 2006 Treatment of chronic hepatitis B José M. Sánchez-Tapias Liver Unit Hospital Clínic University of Barcelona Spain CHRONIC HBV INFECTION
More informationHow to use pegylated Interferon for Chronic Hepatitis B in 2015
How to use pegylated Interferon for Chronic Hepatitis B in 215 Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology Prince of Songkla University, Thailand ASIAN-PACIFIC CLINICAL PRACTICE
More informationHepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &
More informationChronic hepatitis B is one of the leading causes of hepatocellular. Surrogate End Points and Long-Term Outcome in Patients With Chronic Hepatitis B
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:1113 1120 Surrogate End Points and Long-Term Outcome in Patients With Chronic Hepatitis B VINCENT WAI SUN WONG,*, GRACE LAI HUNG WONG,*, ANGEL MEI LING CHIM,*,
More informationChronic hepatitis B - New goals, new treatment. New England Journal Of Medicine, 2008, v. 359 n. 23, p
Title Chronic hepatitis B - New goals, new treatment Author(s) Lai, CL; Yuen, MF Citation New England Journal Of Medicine, 2008, v. 359 n. 23, p. 2488-2491 Issued Date 2008 URL http://hdl.handle.net/10722/59270
More informationHepatitis B Treatment Pearls. Agenda
Hepatitis B Treatment Pearls Fredric D. Gordon, MD Vice Chair Dept. of Transplantation and Hepatobiliary Diseases Lahey Hospital & Medical Center Associate Professor of Medicine Tufts Medical School Boston,
More informationChoice of Oral Drug for Hepatitis B: Status Asokananda Konar
Choice of Oral Drug for Hepatitis B: Status 2011 Asokananda Konar Chronic hepatitis B (CHB) is a global public health challenge with an estimated 350 to 400 million people with chronic HBV infection, despite
More informationThe Impact of HBV Therapy on Fibrosis and Cirrhosis
The Impact of HBV Therapy on Fibrosis and Cirrhosis Jordan J. Feld, MD, MPH Associate Professor of Medicine University of Toronto Hepatologist Toronto Centre for Liver Disease Sandra Rotman Centre for
More informationTreatment as a form of liver cancer prevention The clinical efficacy and cost effectiveness of treatment across Asia
Treatment as a form of liver cancer prevention The clinical efficacy and cost effectiveness of treatment across Asia Prof. Henry LY Chan Head, Division of Gastroenterology and Hepatology Director, Institute
More informationAntiviral Therapy 14:
Antiviral Therapy 14:679 685 Original article Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy Man-Fung Yuen 1 *,
More informationHBV (AASLD) CHB, HBV, CHB , ( < 5% ) 11 ( immune tolerant phase) : 21 ( immune clearance phase ) : 31 ( inactive phase) : HBeAg - HBe HBV DNA ALT
2010262 125 R51216 + 2 C 1001-5256 (2010) 02-0125 - 06 2005 12 [ 1 ], (HBV ) (APASL) ( EASL ) (AASLD) (CHB) [ 2 4 ], ( ) ( ), CHB,, CHB CHB,, CHB,, 2 1 HBV hepatitis B virus CHB chronic hepatitis B HB
More informationNatural History of HBV Infection
Natural History of HBV Infection Joseph JY Sung MD PhD Institute of Digestive Disease Department of Medicine & Therapeutics Prince of Wales Hospital The Chinese University of Hong Kong HBV Infection 2
More informationWho to Treat? Consider biopsy Treat. > 2 ULN Treat Treat Treat Treat CIRRHOTIC PATIENTS Compensated Treat HBV DNA detectable treat
Who to Treat? Parameter AASLD US Algorithm EASL APASL HBV DNA CRITERIA HBeAg+ >, IU/mL > 2, IU/mL > 2, IU/mL >, IU/mL HBeAg- > 2, IU/mL > 2, IU/mL > 2, IU/mL > 2, IU/mL ALT CRITERIA PNALT 1-2 ULN Monitor
More informationEvaluation of Impact of Serial Hepatitis B Virus DNA Levels on Development of Hepatocellular Carcinoma
JOURNAL OF CLINICAL MICROBIOLOGY, June 2009, p. 1830 1836 Vol. 47, No. 6 0095-1137/09/$08.00 0 doi:10.1128/jcm.00029-09 Copyright 2009, American Society for Microbiology. All Rights Reserved. Evaluation
More informationChronic hepatitis B virus (HBV) infection remains a major
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2010;8:541 545 Hepatitis B Virus DNA Level Predicts Hepatic Decompensation in Patients With Acute Exacerbation of Chronic Hepatitis B WEN JUEI JENG, I SHYAN SHEEN,
More informationChronic Hepatitis B: management update.
Chronic Hepatitis B: management update. E.O.Ogutu Department of clinical medicine & therapeutics, University of Nairobi. Physicians meeting,kisumu 2011. Background epidemiology Chronic hepatitis B (CHB)
More informationHepatitis B Virus Genotype C Is Associated With More Severe Liver Fibrosis Than Genotype B
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:1361 1366 Hepatitis B Virus Is Associated With More Severe Liver Fibrosis Than HENRY LIK YUEN CHAN, GRACE LAI HUNG WONG, CHI HANG TSE, ANGEL MEI LING CHIM,
More informationRole of Hepatitis B Virus Genotypes in Chronic Hepatitis B Exacerbation
BRIEF REPORT Role of Hepatitis B Virus Genotypes in Chronic Hepatitis B Exacerbation Man-Fung Yuen, 1 Erwin Sablon, 2 Danny Ka-Ho Wong, 1 He-Jun Yuan, 1 Benjamin Chun-Yu Wong, 1 Annie On-On Chan, 1 and
More informationHBV Diagnosis and Treatment
HBV Diagnosis and Treatment Anna S. F. Lok, MD Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research University of Michigan Ann Arbor, MI, USA
More informationScottish Medicines Consortium
Scottish Medicines Consortium pegylated Interferon alfa 2a, 180 mcg for subcutaneous injection (Pegasys ) No. (186/05) Roche New indication (chronic hepatitis B) 10 June 2005 The Scottish Medicines Consortium
More informationHBeAg-positve chronic hepatts B: Why do I treat my patent with a NA? Maria But
HBeAg-positve chronic hepatts B: Why do I treat my patent with a NA? Maria But Hospital Universitario Valle Hebron and Ciberehd del Insttuto Carlos III. Barcelona. Spain Disclosures Advisory board of,
More informationLong-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease
Antiviral Therapy 12:1295 133 Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease Man-Fung Yuen, Wai-Kay
More informationChronic HBV Management in 2013
Chronic HBV Management in 2013 Mohammad Hossein Somi MD Professor of Gastroentrology and hepatology Liver and Gastrointestinal Disease Research Center Tabriz University of Medical Sciences 1 HBV in 2013
More informationDoes Viral Cure Prevent HCC Development
Does Viral Cure Prevent HCC Development Prof. Henry LY Chan Head, Division of Gastroenterology and Hepatology Director, Institute of Digestive Disease Director, Center for Liver Health Assistant Dean,
More informationAntiviral Therapy 2012; 17: (doi: /IMP1945)
Antiviral Therapy 2012; 17:387 394 (doi: 10.3851/IMP1945) Original article HBV DNA level at 24 weeks is the best predictor of virological response to adefovir add-on therapy in patients with lamivudine
More informationMedInform. HBsAg-guided extension of Peg-IFN therapy in HBeAg-negative responders. Original Article
HBsAg-guided extension of Peg-IFN therapy in HBeAg-negative responders Nina Nikolova, Deian Jelev, Krassimir Antonov, Lyudmila Mateva, Zahariy Krastev. University Hospital St. Ivan Rilski Sofia, Clinic
More informationNew therapeutic perspectives in HBV: when to stop NAs
Liver International ISSN 1478-3223 REVIEW ARTICLE New therapeutic perspectives in HBV: when to stop NAs Cristina Perez-Cameo, Monica Pons and Rafael Esteban Liver Unit, Department of Internal Medicine,
More informationDurability Of Lamivudine Associated HBe Antigen Seroconversion in Chinese-Canadian Patients with Chronic Hepatitis B Virus Infection
ISPUB.COM The Internet Journal of Gastroenterology Volume 4 Number 2 Durability Of Lamivudine Associated HBe Antigen Seroconversion in Chinese-Canadian Patients with Chronic Hepatitis B Virus Infection
More informationViral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg
Viral Hepatitis The Preventive Potential of Antiviral Therapy Thomas Berg Therapeutic and preventive strategies in patients with hepatitis virus infection Treatment of acute infection Treatment of chronic
More informationCURRENT TREATMENT. Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia
CURRENT TREATMENT OF HBV Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia CHRONIC HBV INFECTION DEMOGRAPHICS IN THE USA Estimated
More informationChronic hepatitis B (CHB) is the leading cause of
GASTROENTEROLOGY 2013;144:933 944 CLINICAL LIVER Accuracy of Risk Scores for Patients With Chronic Hepatitis B Receiving Entecavir Treatment GRACE LAI HUNG WONG, 1,2 HENRY LIK YUEN CHAN, 1,2 HOI YUN CHAN,
More informationJournal of Antimicrobial Chemotherapy Advance Access published April 25, 2013
Journal of Antimicrobial Chemotherapy Advance Access published April 25, 213 J Antimicrob Chemother doi:1.193/jac/dkt147 Virological response to entecavir reduces the risk of liver disease progression
More informationOptimized HBV Treatment Through Baseline and on-treatment Predictor Oral Antiviral Therapy. Watcharasak Chotiyaputta
Optimized HBV Treatment Through Baseline and on-treatment Predictor Oral Antiviral Therapy Watcharasak Chotiyaputta Progression of Liver Disease Goal of HBV Treatment: prevention the development of cirrhosis
More informationTreatment of chronic hepatitis B 2013 update
22 February 213 Treatment of chronic hepatitis B 213 update Pietro Lampertico 1st Gastroenterology Unit Fondazione IRCCS Cà Granda - Ospedale Maggiore Policlinico Università di Milano EASL 212 Clinical
More informationNUCs for Chronic Hepatitis B. Rafael Esteban Hospital Universitario Valle Hebron and Ciberehd del Instituto Carlos III. Barcelona.
NUCs for Chronic Hepatitis B Rafael Esteban Hospital Universitario Valle Hebron and Ciberehd del Instituto Carlos III. Barcelona. Spain Disclosures Advisory board of, and/or, received speaker fee from
More informationIs there a need for combination therapy? No. Maria Buti Hospital General Universitario Valle Hebron Barcelona. Spain
Is there a need for combination therapy? No Maria Buti Hospital General Universitario Valle Hebron Barcelona. Spain No, No and No EASL Update HBV Guidelines 2012 The most potent drugs with the optimal
More informationManagement of Decompensated Chronic Hepatitis B
Management of Decompensated Chronic Hepatitis B Dr James YY Fung, FRACP, MD Department of Medicine The University of Hong Kong Liver Transplant Center Queen Mary Hospital State Key Laboratory for Liver
More informationESCMID Online Lecture Library. by author
Pro-Con: To stop or not to stop hepatitis B treatment? To Stop HBV Treatment Resat Ozaras, MD, Professor Istanbul University, Cerrahpasa Medical School, Infection Dept. HBV Therapy Nucleos(t)ide analogues
More informationHepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients
Hepatol Int (2013) 7:88 97 DOI 10.1007/s12072-012-9343-x ORIGINAL ARTICLE Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative
More informationConsensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition
Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition Anna S. Lok, MD, DSc Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research
More informationJ.C. WANG, L.L. HE, Q. CHEN 1. Introduction. Abstract. BACKGROUND: Either combination. European Review for Medical and Pharmacological Sciences
European Review for Medical and Pharmacological Sciences Comparison of re-treatment outcomes of lamivudine plus adefovir or entecavir in chronic hepatitis B patients with viral relapse after cessation
More informationIntron A HEPATITIS B. Intron A (interferon alfa-2b) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.03.01 Subject: Intron A Hepatitis B Page: 1 of 8 Last Review Date: September 18, 2015 Intron A HEPATITIS
More informationOriginal article On-treatment monitoring of liver fibrosis with transient elastography in chronic hepatitis B patients
Antiviral Therapy 2011; 16:165 172 (doi: 10.3851/IMP1726) Original article On-treatment monitoring of liver fibrosis with transient elastography in chronic hepatitis B patients Grace Lai-Hung Wong 1,2,
More informationPegasys Pegintron Ribavirin
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.47 Subsection: Anti-infective nts Original Policy Date: January 1, 2019 Subject: Pegasys Pegintron
More informationGish RG and AC Gadano. J Vir Hep
Treatment in Hepatitis B and C There are options! Karen F. Murray, MD Professor of Pediatrics Director, Hepatobiliary Program Seattle Children s Hepatitis B Virus Epidemiology and natural history 400
More informationDrug Class Monograph
Drug Class Monograph Class: Chronic Hepatitis B Drug: Baraclude (entecavir), Epivir (lamivudine), Hepsera (adefovir), Intron A (interferon alfa- 2b), Pegasys (peginterferon alfa-2a), Tyzeka (telbivudine),
More informationARTICLE IN PRESS. A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: An Update
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:xxx REVIEW A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: An Update EMMET B. KEEFFE,* DOUGLAS T. DIETERICH,
More informationDisclaimer. Presenter Release are for reactive use by Medical Information only internal learning/educational use only
Disclaimer Presenter Release are for reactive use by Medical Information only internal learning/educational use only Any unsolicited request from HCP must be forwarded to Medical Information Housekeeping
More informationRecent achievements in the treatment of hepatitis B by nucleosides and nucleotides. K. Zhdanov
EASL endorsed conference White Nights of Hepatology 2012 Adverse events during antiviral therapy: how to predict, manage and monitor June 7-8 Saint-Petersburg Recent achievements in the treatment of hepatitis
More informationDual Therapy for Chronic Hepatitis B Virus
Dual Therapy for Chronic Hepatitis B Virus Hussien Elsiesy, MD, and Douglas Dieterich, MD Corresponding author Douglas Dieterich, MD Division of Liver Diseases, Mount Sinai School of Medicine, One Gustave
More informationThe importance of the serum quantitative levels of hepatitis B surface antigen and hepatitis B e antigen in children with chronic hepatitis B
The importance of the serum quantitative levels of hepatitis B surface antigen and hepatitis B e antigen in children with chronic hepatitis B LIVER Kaan Demirören, Halil Kocamaz, Yaşar Doğan Department
More informationPegasys Hepatitis B. Pegasys (peginterferon alfa-2a) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.03.02 Subject: Pegasys Hepatitis B Page: 1 of 5 Last Review Date: September 18, 2015 Pegasys Hepatitis
More informationSYNOPSIS OF RESEARCH REPORT (PROTOCOL MV22009)
SYNOPSIS OF RESEARCH REPORT 1066781 (PROTOCOL MV22009) COMPANY: F. Hoffmann-La Roche, Ltd ME OF FINISHED PRODUCT: Pegasys ME OF ACTIVE SUBSTANCE(S): Peginterferon alfa-2a (FOR TIOL AUTHORITY USE ONLY)
More informationChronic Hepatitis B - Antiviral Resistance in Korea -
Chronic Hepatitis B - Antiviral Resistance in Korea - Young-Suk Lim University of Ulsan College of Medicine Asan Medical Center Seoul, Korea HBV Genome partially double-stranded DNA genome about 3200 nucleotides
More informationManagement of hepatitis B virus
Journal of Antimicrobial Chemotherapy Advance Access published May 14, 2008 Journal of Antimicrobial Chemotherapy doi:10.1093/jac/dkn188 Management of hepatitis B virus Nidhi A. Singh and Nancy Reau* Section
More informationCLINICAL LIVER, PANCREAS, AND BILIARY TRACT
GASTROENTEROLOGY 2008;134:405 415 BILIARY TRACT Virologic Monitoring of Hepatitis B Virus Therapy in Clinical Trials and Practice: Recommendations for a Standardized Approach JEAN MICHEL PAWLOTSKY,*, GEOFFREY
More informationTherapeutic Guidelines on Management of Chronic Hepatitis B in Asia
SPECIAL FEATURE Vol.6 No.2 (April 2001) Therapeutic Guidelines on Management of Chronic Hepatitis B in Asia Abstract Dr. Nancy Leung Department of Medicine and Therapeutics, Prince of Wales Hospital, The
More informationHepatocellular Carcinoma: Can We Slow the Rising Incidence?
Hepatocellular Carcinoma: Can We Slow the Rising Incidence? K.Rajender Reddy M.D. Professor of Medicine Director of Hepatology Medical Director of Liver Transplantation University of Pennsylvania Outline
More informationPotential Efficacy of Pegylated Interferon-α and a Nucleos(t)ide Analogue as Combination Therapy for HBeAg-Positive Chronic Hepatitis B
Gut and Liver, Vol. 10, No. 4, July 2016, pp. 611-616 ORiginal Article Potential Efficacy of Pegylated Interferon-α and a Nucleos(t)ide Analogue as Combination Therapy for HBeAg-Positive Chronic Hepatitis
More informationWhats new on HBsAg and other markers for HBV infection? Christoph Höner zu Siederdissen
Whats new on HBsAg and other markers for HBV infection? Christoph Höner zu Siederdissen Why diagnostic markers are important They are the basis for clinical decision makings treatment or no treatment?
More informationAn Update HBV Treatment
An Update HBV Treatment Epidemiology Natural history Treatment Daryl T.-Y. Lau, MD, MPH Associate Professor of Medicine Director of Translational Liver Research Division of Gastroenterology BIDMC, Harvard
More informationA Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2015 Update
Accepted Manuscript A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2015 Update Paul Martin, MD, Daryl T.-Y. Lau, MD, MSc, MPH, Mindie H. Nguyen, MD,
More informationPeginterferon alfa-2a (40 kd; PEG-IFNa-2a) has
Shorter Durations and Lower Doses of Peginterferon alfa-2a Are Associated with Inferior Hepatitis B e Antigen Seroconversion Rates in Hepatitis B Virus Genotypes B or C Y.-F. Liaw, 1 J.-D. Jia, 2 H.L.Y.
More informationHepatitis B Prior Authorization Policy
Hepatitis B Prior Authorization Policy Line of Business: Medi-Cal P&T Approval Date: November 15, 2017 Effective Date: January 1, 2018 This policy has been developed through review of medical literature,
More informationIdentification of hepatitis B virus DNA reverse transcriptase variants associated with partial response to entecavir
Title Identification of hepatitis B virus DNA reverse transcriptase variants associated with partial response to entecavir Author(s) Wong, DKH; Fung, JYY; Lai, CL; Yuen, RMF Citation Hong Kong Medical
More informationNatural History of Chronic Hepatitis B
Natural History of Chronic Hepatitis B Anna SF Lok, MD Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research University of Michigan Ann Arbor,
More informationChronic Hepatitis B: A Treatment Update
122 Chronic Hepatitis B: A Treatment Update Vincent Wong, MD 1,2 Henry Chan, MD 1,2 1 Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong 2 Institute of Digestive Disease,
More informationThe role of entecavir in the treatment of chronic hepatitis B
REVIEW The role of entecavir in the treatment of chronic hepatitis B Evangelini Dimou Vasilios Papadimitropoulos Stephanos J Hadziyannis Department of Medicine and Liver Unit, Henry Dunant Hospital, Athens,
More informationA 20 year-old university student Known chronic HBV infection since he was 12 year-old.
Case 1 A 20 year-old university student Known chronic HBV infection since he was 12 year-old. His father died from HCC. Two of his 3 brothers also have chronic hepatitis B Still asymptomatic with persistent
More informationHepatitis B. Epidemiology and Natural History and Implications for Treatment
Hepatitis B Epidemiology and Natural History and Implications for Treatment Norah Terrault, MD Professor of Medicine and Surgery Director, Viral Hepatitis Center University of California San Francisco
More informationHepatitis B and Interferon Philippe Sogni Paris-Descartes University, INSERM U-1016 and Hepatology unit, Cochin hospital, Paris; France PHC 2015
Hepatitis B and Interferon Philippe Sogni Paris-Descartes University, INSERM U-1016 and Hepatology unit, Cochin hospital, Paris; France PHC 2015 1 Prof. Philippe SOGNI, M.D., Ph.D. Affiliations Institut
More informationThe presence of hepatitis B e antigen (HBeAg) is
Assessment of Current Criteria for Primary Nonresponse in Chronic Hepatitis B Patients Receiving Entecavir Therapy Young-Joo Yang, 1 Ju Hyun Shim, 2 Kang Mo Kim, 2 Young-Suk Lim, 2 and Han Chu Lee 2 A
More informationTreatment of chronic hepatitis B: Evolution over two decades_
doi:10.1111/j.1440-1746.2010.06545.x REVIEW Treatment of chronic hepatitis B: Evolution over two decades_6545 138..143 Man-Fung Yuen and Ching-Lung Lai Department of Medicine, the University of Hong Kong,
More informationIndividualizing Treatment in the Patient With Chronic HBV Infection: When to Start, What to Use, and When to Stop CME
Individualizing Treatment in the Patient With Chronic HBV Infection: When to Start, What to Use, and When to Stop CME Chia C. Wang, MD, MS Anna S. F. Lok, MD Kris V. Kowdley, MD Supported by an independent
More informationMedInform. HBV DNA loss in Bulgarian patients on NUC therapy. Speed related factors. (NUC related speed of HBV DNA loss in Bulgaria) Original Article
DOI: 10.18044/Medinform.201852.897 ISSUE 3, 2018 HBV DNA loss in Bulgarian patients on NUC therapy. Speed related factors. (NUC related speed of HBV DNA loss in Bulgaria) Donika Krasteva, Radosveta Tomova,
More informationSupplementary materials: Predictors of response to pegylated interferon in chronic hepatitis B: a
Supplementary materials: Predictors of response to pegylated interferon in chronic hepatitis B: a real-world hospital-based analysis Yin-Chen Wang 1, Sien-Sing Yang 2*, Chien-Wei Su 1, Yuan-Jen Wang 3,
More informationDr David Rowbotham NHS. The Leeds Teaching Hospitals. NHS Trust
Dr David Rowbotham The Leeds Teaching Hospitals NHS Trust NHS Nurses Update June 2010 Chronic Hepatitis HBV / HCV David Rowbotham Clinical Director & Consultant Gastroenterologist Dept of Gastroenterology
More informationA Preliminary Study on the Safety and Efficacy of HD-03/ES Therapy in Patients with Chronic Hepatitis B
C linical S tudy Janardan Singh* Anupam Chakraborty* Mukul Chandra Dhar* Sudhakaran C** Mitra SK** A Preliminary Study on the Safety and Efficacy of HD-03/ES Therapy in Patients with Chronic Hepatitis
More informationSustained Responses and Loss of HBsAg in HBeAg-Negative Patients With Chronic Hepatitis B Who Stop Long-Term Treatment With Adefovir
GASTROENTEROLOGY 2012;143:629 636 Sustained Responses and Loss of HBsAg in HBeAg-Negative atients With Chronic Hepatitis B Who Stop Long-Term Treatment With Adefovir STEHANOS J. HADZIYANNIS,*, VASSILIOS
More informationHepatitis B Update. Jorge L. Herrera, M.D. University of South Alabama Mobile, AL. Gastroenterology
Hepatitis B Update Jorge L. Herrera, M.D. University of South Alabama Mobile, AL Deciding Who to Treat Is hepatitis B a viral disease or a liver disease? Importance of HBV-DNA Levels in the Natural History
More informationDiagnostic Methods of HBV and HDV infections
Diagnostic Methods of HBV and HDV infections Zohreh Sharifi,ph.D Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine Hepatitis B-laboratory diagnosis Detection
More informationentecavir, 0.5mg and 1mg film-coated tablets and 0.05 mg/ml oral solution, Baraclude SMC No. (747/11) Bristol-Myers Squibb Pharmaceuticals Ltd
entecavir, 0.5mg and 1mg film-coated tablets and 0.05 mg/ml oral solution, Baraclude SMC No. (747/11) Bristol-Myers Squibb Pharmaceuticals Ltd 09 December 2011 The Scottish Medicines Consortium (SMC) has
More informationViral hepatitis and Hepatocellular Carcinoma
Viral hepatitis and Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline
More informationFebruary 8, World Journal of Gastroenterology. Re: ESPS Manuscript No Dear Dr. Qi:
February 8, 2017 World Journal of Gastroenterology Re: ESPS Manuscript No. 32025 Dear Dr. Qi: My co-authors and I respectfully submit the accompanying revised manuscript, Early hepatitis B viral DNA clearance
More informationScottish Medicines Consortium
Scottish Medicines Consortium tenofovir disoproxil (as fumarate), 245 mg film-coated tablet (Viread ) No. (479/08) Gilead Sciences 06 June 2008 The Scottish Medicines Consortium has completed its assessment
More informationSeroclearance of the hepatitis B surface antigen
A Large Case-Control Study on the Predictability of Hepatitis B Surface Antigen Levels Three Years Before Hepatitis B Surface Antigen Seroclearance Wai-Kay Seto, 1 Danny Ka-Ho Wong, 1 James Fung, 1 Ivan
More informationHBV NATURAL HISTORY. Mitchell L. Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia
HBV NATURAL HISTORY AND MANAGMENT Mitchell L. Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia IVer Liver Institute of Virginia Education,
More informationPersonalized treatment of hepatitis B
pissn 2287-2728 eissn 2287-285X Review Clinical and Molecular Hepatology 2015;21:1-6 Personalized treatment of hepatitis B Anna S. Lok Division of Gastroenterology and Hepatology, University of Michigan,
More informationCurrently status of HBV therapy: efficacy and limitations
9 November 2016 Currently status of HBV therapy: efficacy and limitations Pietro Lampertico Gastroenterology and Hepatology Unit Fondazione IRCCS Cà Granda - Ospedale Maggiore Policlinico University of
More informationEndpoints of hepatitis B treatment
Journal of Viral Hepatitis, 2010, 17, 675 684 doi:10.1111/j.1365-2893.2010.01369.x REVIEW Endpoints of hepatitis B treatment W. Chotiyaputta and A. S. F. Lok Division of Gastroenterology, Department of
More informationMin Weng, Wei-Zheng Zeng *, Xiao-Ling Wu, Yong Zhang, Ming-De Jiang, Zhao Wang, De-Jiang Zhou and Xuan He
Weng et al. Virology Journal 2013, 10:277 RESEARCH Open Access Quantification of serum hepatitis B surface antigen in predicting the response of pegylated interferon alfa-2a in HBeAg-positive chronic hepatitis
More informationAn estimated 400 million people worldwide are chronically
GASTROENTEROLOGY 2010;139:1218 1229 Tenofovir and Entecavir Are the Most Effective Antiviral Agents for Chronic Hepatitis B: A Systematic Review and Bayesian Meta-analyses GLORIA WOO,*, GEORGE TOMLINSON,*,,
More information